Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580190 · ClinicalTrials.gov registry record · Phase 1
Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00580190 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 47 participants.
The verdict
NCT00580190, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and cortisol responses to naloxone by blocking the effect of the CRH increases induced by naloxone at the postsynaptic receptors. Demonstration of a statistically significant attenuation of naloxone induced increases in cortisol and/or ACTH concentrations by PF-00572778 compared to placebo would thus constitute proof of mechanism for the compound. Therefore, this study is to evaluate pharmacodynamic effects of PF-00572778 following naloxone challenge in healthy subjects.
Interventions
- OTHER Placebo
- DRUG alprazolam
- DRUG PF-00572778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580190
The ClinicalTrials.gov registry entry for NCT00580190 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00580190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580190 about?
NCT00580190 is a clinical study titled "Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects". PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and cortisol responses to naloxone by blocking the effect of the CRH increases induced by naloxone at the postsynaptic receptors. Demonstration of a statistically significant attenuation of naloxone induced increases ...
What is the current status of trial NCT00580190?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2007-09. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00580190?
The interventions under investigation include: Placebo (OTHER), alprazolam (DRUG), PF-00572778 (DRUG).
Who is sponsoring clinical trial NCT00580190?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.